At the highest doses, retatrutide seems to promise more significant weight loss than existing GLP-1s on the market but as dosage increases, so does the risk of side effects, mostly mild-to-moderate gastrointestinal issues, although one case of pancreatitis occurred in a patient on the 12mg dose during the phase II trial
Clinical and mechanistic outcomes are planned and inflammatory changes from baseline will be assessed in subcutaneous abdominal adipose and respiratory tract samples
Cell culture and viability measurements KGN was obtained from Otwobio Biotech (Guangzhou) Inc
The Bottom Line For patients and clinicians, the choice between these therapies depends on: Desired weight loss Convenience and preference (oral vs injectable) Tolerance of side effects Insurance and accessibility Retatrutide leads in efficacy but may bring more side effects
You can indicate a treatment preference, but the final decision rests with the prescribing specialist based on your clinical profile
In this intimate conversation, Sakara founder Danielle DuBoise joins bestselling author Martha Beck to reframe anxietynot as a personal flaw, but as misdirected creative energy